trial

A Safety and PK Study of Injectable Risperidone-SABER and the DosePro Delivery System in Patients With Schizophrenia

NCTId NCT01592110
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 40 (actual)
Sponsored by Zogenix, Inc.
Primary completion 2013-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
40 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2012-07
Primary completion
2013-04
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Risperidone

Sponsors

Zogenix, Inc.Lead Sponsor

Investigators

1
Lev G Gertsik, MDPrincipal Investigator

Sites

1 total
Glendale, United States

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE1
Primary Completion Date
2013-04
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
lead_sponsor
Zogenix, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Lev G Gertsik, MD
person